Skip to main content
. Author manuscript; available in PMC: 2022 Dec 2.
Published in final edited form as: Cancer Gene Ther. 2020 Jul 7;28(1-2):98–111. doi: 10.1038/s41417-020-0189-4

Figure 3. Immune status in the TME and spleen post virus treatment.

Figure 3.

B6 mice were inoculated subcutaneously with 5.0e5 MC38 tumor cells. When tumors reached 5 × 5 mm (about day 9) they were treated intratumorally with PBS, vvDD, vvDD-IL-2 at a dose of 1.0e8 PFU. The mice were sacrificed 10 days post viral treatment and primary tumors and splenocytes were collected and analyzed by flow cytometry to determine the activation and immunosuppressive markers in (A) splenocytes, (B) TILs and (C) subsets of CD8+ T cells in the TILs. Tn for naïve T cells; Tcm for central memory T cells, and Tem for effector memory T cells. The percentages are over total CD8+ T cells, or over total CD4+ T cells for Treg cells. * p < 0.05, ** p < 0.01, *** p < 0.001; **** p < 0.0001.